Insight

Photo taken from Fred Saad/X

Sep 26, 2024, 12:37

Exclusive Interview With Fred Saad

MediaMedic shared on LinkedIn:

“Exclusive Insights on mHSPC Treatment: Interview with Fred Saad.

In a recent Media Medic interview, our colleague El Bachir Mourabit had the privilege to speak with Dr. Fred Saad about breakthrough advancements in metastatic hormone-sensitive prostate cancer (mHSPC) treatment.

Dr. Saad emphasized the importance of combining androgen deprivation therapy (ADT) with ARPIs like apalutamide, enzalutamide, or abiraterone for improved survival.

He also shared promising results from the Phase 3 ARINOTE study, showcasing darolutamide with ADT as a safe and effective option, especially for patients who may not tolerate chemotherapy.”

Source: MediaMedic/LinkedIn

abiraterone androgen deprivation therapy apalutamide cancer chemotherapy darolutamide El Bachir Mourabit Enzalutamide Fred Saad MediaMedic mHSPC treatment OncoDaily Oncology

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer